Two Sigma Advisers LP Invests $662,000 in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Two Sigma Advisers LP purchased a new position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 49,700 shares of the company’s stock, valued at approximately $662,000. Two Sigma Advisers LP owned about 0.19% of Eton Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Nantahala Capital Management LLC boosted its stake in shares of Eton Pharmaceuticals by 12.0% in the fourth quarter. Nantahala Capital Management LLC now owns 1,118,483 shares of the company’s stock worth $14,898,000 after acquiring an additional 119,750 shares during the last quarter. Mink Brook Asset Management LLC acquired a new position in Eton Pharmaceuticals during the fourth quarter worth $6,071,000. Cannell Capital LLC acquired a new position in Eton Pharmaceuticals during the fourth quarter worth $5,079,000. Parkman Healthcare Partners LLC boosted its stake in Eton Pharmaceuticals by 6.4% during the fourth quarter. Parkman Healthcare Partners LLC now owns 276,890 shares of the company’s stock worth $3,688,000 after buying an additional 16,664 shares during the last quarter. Finally, Aristides Capital LLC boosted its stake in Eton Pharmaceuticals by 20.8% during the fourth quarter. Aristides Capital LLC now owns 241,587 shares of the company’s stock worth $3,218,000 after buying an additional 41,587 shares during the last quarter. 27.86% of the stock is owned by institutional investors and hedge funds.

Eton Pharmaceuticals Stock Down 8.3%

NASDAQ:ETON opened at $17.28 on Wednesday. Eton Pharmaceuticals, Inc. has a 52 week low of $3.18 and a 52 week high of $21.48. The company has a market capitalization of $463.42 million, a P/E ratio of -78.55 and a beta of 1.22. The stock’s fifty day moving average is $16.00 and its two-hundred day moving average is $14.78.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Tuesday, May 13th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The business had revenue of $17.28 million during the quarter, compared to analysts’ expectations of $14.33 million. Sell-side analysts anticipate that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ETON. Craig Hallum boosted their price objective on Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday, May 14th. HC Wainwright reissued a “buy” rating and set a $35.00 price objective (up previously from $33.00) on shares of Eton Pharmaceuticals in a research note on Thursday, May 29th. Finally, B. Riley reissued a “buy” rating and set a $26.00 price objective (up previously from $24.00) on shares of Eton Pharmaceuticals in a research note on Friday, May 16th.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.